Likopid 0.001 N10 tablets

Active ingredients Glucosaminyl muramyldipeptide

Country of originRussia

ManufacturerPeptek, JSC

Release form Tablets of 1 mg - 10 pcs per pack.

Store in a dry place

Store in a dark place

Keep out of reach of children

Dosage form

White round flat-cylindrical tablets with beveled

Structure

Active substance:

glucosaminylmuramyl dipeptide (GMDP) - 1.0 mg.

Excipients: lactose monohydrate - 73.88 mg, sugar (sucrose) 5.0 mg, potato starch - 19.0 mg, methylcellulose - 0.12 mg, calcium stearate - 1.0 mg.

general description

Immunomodulating agent.

Special conditions

At the beginning of taking Likopid® 1 mg, an exacerbation of symptoms of chronic and latent diseases is possible, associated with the main pharmacological effects of the drug.

Influence on the ability to drive vehicles, mechanisms

Does not affect the ability to drive a car and complex mechanisms.

Drug interactions

The drug increases the effectiveness of antimicrobial drugs, there is synergy with antiviral and antifungal drugs.

Antacids and sorbents significantly reduce the bioavailability of the drug.

Glucocorticosteroids reduce the biological effect of Likopid®.

Pharmacodynamics

The active ingredient of Likopid® tablets - glucosaminylmuramyl dipeptide (GMDP) - is a synthetic analogue of the structural fragment of the membrane (peptidoglycan) of bacterial cells.

GMDP is an activator of innate and acquired immunity, enhances the body's defense against viral, bacterial and fungal infections

has an adjuvant effect in the development of immunological reactions.

The biological activity of the drug is realized through the binding of GMDP to the intracellular receptor protein NOD2, localized in the cytoplasm of phagocytes (neutrophils, macrophages, dendritic cells). The drug stimulates the functional (bactericidal, cytotoxic) activity of phagocytes, enhances the presentation of antigens by them, the proliferation of T- and B-lymphocytes, increases the synthesis of specific antibodies, helps to normalize the balance of Th1 / Th2 lymphocytes towards the prevalence of Th1. The pharmacological action is carried out by increasing the production of key interleukins (interleukin-1, interleukin-6, interleukin-12), tumor necrosis factor alpha, gamma-interferon, colony-stimulating factors. The drug increases the activity of natural killer cells.

Likopid® has low toxicity (LD50 exceeds the therapeutic dose by more than 49,000 times).

In the experiment, with the oral route of administration in doses 100 times higher than the therapeutic one, the drug has no toxic effect on the central nervous and cardiovascular systems, does not cause pathological changes in the internal organs.

Likopid® does not have embryotoxic and teratogenic effects, does not cause chromosomal, gene mutations.

In experimental studies carried out on animals, data on the antitumor activity of Likopid® (GMDP) were obtained.

Pharmokinetics

The oral bioavailability of the drug is 7-13%.

The degree of binding to blood albumin is weak.

The time to reach the maximum concentration (tmax) is 1.5 hours after administration.

The half-life (t1 / 2) is 4.29 hours.

It does not form active metabolites, it is excreted mainly through the kidneys unchanged.

Indications

The drug is used in adults and children (from 3 years old) in the complex therapy of diseases accompanied by secondary immunodeficiency states:

Children:

- chronic, recurrent infections of the upper and lower respiratory tract in the stage of exacerbation and in the stage of remission

- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others)

- herpes infection.

Adults:

- chronic respiratory tract infections

- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others

- herpes infection.

Preventive reception (adults):

- prevention and reduction of seasonal incidence of acute respiratory infections and the frequency of exacerbations of chronic diseases of ENT organs, upper and lower respiratory tract.

Contraindications

Hypersensitivity to glucosaminylmuramyldipeptide and other components of the drug

pregnancy and breastfeeding

autoimmune thyroiditis in the acute phase

conditions accompanied by febrile temperature (> 38 ° C) at the time of taking the drug

rare congenital metabolic disorders: alactasia, galactosemia, lactase deficiency, lactose intolerance, sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption

use in autoimmune diseases is not recommended due to lack of clinical data.

Application during pregnancy and during breastfeeding

Taking Likopid® 1 mg is contraindicated in women during pregnancy and breastfeeding.

Overdose

Cases of drug overdose are unknown.

Based on the pharmacological properties of the drug, in case of an overdose, the body temperature may rise to subfebrile (up to 37.9 ° C) values.

If necessary, symptomatic therapy (antipyretic drugs) is carried out, sorbents are prescribed.

The specific antidote is unknown.

Side effects

Often (1-10%) - at the beginning of treatment, there may be a short-term increase in body temperature to subfebrile values ​​(up to 37.9 ° C), which is not an indication for discontinuation of the drug.

Rarely (0.01-0.1%) - a short-term increase in body temperature to febrile values ​​(> 38.0 ° C).

When the body temperature rises above 38.0 ° C, it is possible to take antipyretic drugs, which does not reduce the pharmacological effects of Likopid® tablets.

Very rare (less than 0.01 - diarrhea.

If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects not listed in the instructions, inform your doctor.

Dosage

1mg

Indications

The drug is used in adults and children (from 3 years old) in the complex therapy of diseases accompanied by secondary immunodeficiency states:

Children: - chronic, recurrent infections of the upper and lower respiratory tract in the stage of exacerbation and in the stage of remission

- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others)

- herpes infection.

Adults: - chronic respiratory tract infections

- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others - herpetic infection. Prophylactic intake (adults): - prevention and reduction of seasonal incidence of acute respiratory infections and the frequency of exacerbations of chronic diseases of the upper and lower respiratory tract ...

Storage conditions and periods

In a dry, dark place at a temperature not exceeding 25 degrees.

Expiration date: 5 years

INN / Active ingredient

Glucosaminylmuramyldipeptide

Contraindications

Hypersensitivity to glucosaminylmuramyldipeptide and other components of the drug

pregnancy and breastfeeding

autoimmune thyroiditis in the acute phase

conditions accompanied by febrile temperature (> 38 ° C) at the time of taking the drug

rare congenital metabolic disorders: alactasia, galactosemia, lactase deficiency, lactose intolerance, sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption

use in autoimmune diseases is not recommended due to lack of clinical data.

Application during pregnancy and during breastfeeding Taking the drug Likopid® 1 mg is contraindicated in women during pregnancy and breastfeeding.

Specifications

Scope of the drug

The immune system

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

ten

Vacation conditions

Without recipe

Brand name

Peptek

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Immunomodulatory agent

Anatomical and therapeutic characteristics

L03A Immunostimulants

Dosage form

Pills

Dosage (volume) of the substance in the preparation

glucosaminylmuramyl dipeptide (GMDP) 1 mg

Expiration date in days

1825

Package weight, g

ten

Category

:

Immunomodulators

,

Immunosuppressants

,

Immunoglobulins

,

Interferons

Information on technical characteristics, delivery set, country of manufacture